PMS2 and adenoma: As seen in Tables 2 and 34%, 34%, 27% and 21% of path_MLH1, path_MSH2, path_MSH6 and path_PMS2 carriers, respectively had one or more adenomas and only a minority (5%, 7%, 5% and 4%, respectively) had more than 3 adenomas.